Navigation Links
Pharsight Strengthens Senior Management Team

John Murphy Appointed as New Senior Vice President of Consulting Services

MOUNTAIN VIEW, Calif., April 29 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it has expanded its management team by appointing John E. Murphy, DrPH, as Senior Vice President of Consulting Services. In this role, Dr. Murphy will lead the Company's two global scientific consulting units focused on the strategic application of model-based drug development and regulatory-compliant PK/PD analysis and reporting services.

Dr. Murphy brings more than 25 years of pharmaceutical industry services, software and strategic management experience to the Pharsight executive team. Prior to joining Pharsight, Dr. Murphy was Principal and Executive Advisor at Booz Allen Hamilton, Inc., where he worked with leading pharmaceutical, biotechnology and high-technology companies developing strategies and implementing solutions to improve R&D productivity. Before this, Dr. Murphy served as Vice President and Chief Information Officer at CuraGen Corporation, a publicly traded biopharmaceutical company. While at CuraGen, he directed business development and information technology services for the company and its pharmaceutical partners and clinical trials network.

"Pharsight's modeling and simulation methodology and accompanying software solutions are on the leading edge of traditional drug development processes and are continuing to gain mindshare in the industry," said Dr. Murphy. "I look forward to working with the senior management team and its world-class scientific consulting groups to further strengthen Pharsight's service offerings that address the growing needs of pharmaceutical and biotechnology companies to more efficiently develop their pipeline of products."

"John's extensive pharmaceutical industry background and experience with companies focused on enabling services and technology for pharmaceutical development will allow him to contribute meaningfully to Pharsight's future growth," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "We believe John's leadership of both Pharsight's scientific consulting units, Strategic Consulting Services (SCS) and Reporting and Analysis Services (RAS), will be particularly valuable as we execute on our plans to expand these teams' capabilities, leverage our industry-leading software, and further enhance the services that we provide to our clients to improve drug development productivity and decision-making. We are very excited to welcome John to Pharsight."

Prior to joining CuraGen, Dr. Murphy was founder and chief executive officer at Just Medicine Incorporated, a developer of regulatory-compliant clinical software for the management of real-time data collection and analysis. He was instrumental in the eventual sale of Just Medicine Incorporated and its clinical network to a joint venture formed by two leading global pharmaceutical companies. Dr. Murphy has also held a number of other senior leadership roles in medical device companies, life sciences software technology companies and healthcare delivery organizations, including Predict Incorporated, Community Health Computing and Mercy Hospital in Watertown, New York.

Before Dr. Murphy began his career in the pharmaceutical industry, he held senior health care policy management and research positions at the Sloan Commission on Government and Higher Education in Washington, DC, at the Massachusetts Institute of Technology, and with the Health Planning Council for Greater Boston. He has lectured on numerous life sciences technology and pharmaceutical research topics, and has authored journal articles in publications such as Health Care Informatics and the New England Journal of Medicine. He is also the author of 17 patents, including 12 approved or pending patents on clinical software and data mining techniques.

Dr. Murphy earned his masters and doctor of Public Health degrees from Columbia University, and throughout his career has completed various software training certifications as well as executive-level programs in healthcare finance and health information systems management.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective holders.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
2. Pharsight Signs New Diabetes Meta-Database Customer
3. Pharsight to Present at eClinical Forum
4. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
5. FDA and Pharsight Continue to Collaborate Under CRADA
6. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
7. Pharsight Achieves $7.3 Million in Quarterly Revenue
8. Pharsight Expands Global Consulting Services Teams
9. Pharsight to Host European Software Conference
10. Pharsight Files Application for Nasdaq Capital Market Listing
11. Life Brokerage Partners Strengthens Premium Finance Programs
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... BAR, CALIF. (PRWEB) , ... ... ... Inc. ( ), a leading provider of enterprise Time and Attendance/Workforce ... Partner status in the Microsoft Partner Program with competencies in the Application ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... in 2016. In 2016, expected coding changes are likely to include new codes ... codes. It’s not easy to understand the effects of code changes in musculoskeletal, ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute of Ultrasound ... process that allows practices to demonstrate that they meet or exceed nationally ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable help with mobility, ... exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a way to address ... benefits of a standard walker to improve the user’s quality of life. To begin ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , November 27, 2015 ... set to go online. The potential to save costs, ... vast and far from fully exploited as yet. Here, ... health records, either via mobile tablet or directly at ... --> ) -->      ...
(Date:11/27/2015)... -- Research and Markets ( ) has announced ... 2015-2019" report to their offering. ... the author the present scenario and growth prospects of ... the market size, the report considers revenue generated from ... and copper IUDs. The report forecasts the global intrauterine ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
Breaking Medicine Technology: